New pill (GFH375) vs chemo for KRAS G12D lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread or cannot be removed with surgery.
- Your cancer has a specific genetic change called KRAS G12D mutation (your doctor can test for this).
- You have already tried at least one round of platinum chemotherapy and one immunotherapy (like Keytruda or Opdivo), but it stopped working or caused too many side effects.
- You have not been treated before with docetaxel (a chemotherapy drug) or any drug that targets KRAS G12D or pan-KRAS.
- Your cancer does not have other major gene changes (like EGFR, ALK, or additional RAS mutations), and it has not spread to your brain or spine in a way that causes symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted drug (JMKX001899) against the chemotherapy docetaxel for people with advanced KRAS G12C-mutant non-small cell lung cancer that has already been treated with chemotherapy and immunotherapy. It aims to see if the new drug works better and has fewer side effects.
This trial tests a new combination of two targeted pills (GH21 and D-1553) for people with advanced solid tumors that have a specific KRAS G12C mutation, especially those who have already tried another KRAS G12C inhibitor. The goal is to see if the combo can shrink tumors more effectively.
This trial compares a new targeted pill (D-1553) against a standard chemotherapy (docetaxel) for people with a specific type of advanced lung cancer (KRAS G12C mutation) whose cancer has stopped responding to first-line immunotherapy and chemotherapy.
This trial tests a new drug called GFH375, either alone or combined with other treatments, for advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if this targeted approach can slow or shrink your cancer better than standard treatments.
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
This trial tests a new drug (HS-10370) combined with other cancer treatments for people with advanced lung cancer that has a specific mutation called KRAS G12C. It is for those who have not yet received systemic therapy for their advanced disease.
Hear when a new KRAS G12D Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.